Neuro-Oncology News

Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.

CHICAGO — Selumetinib appeared effective and safe for the treatment of recurrent or refractory low-grade glioma in children, according to results of a phase 2 clinical trial presented at the ASCO Annual Meeting.

CHICAGO — Routine genomic testing of tumor samples appears feasible and enabled more personalized treatment, according to the results of the ProfiLER study conducted in France and presented at the ASCO Annual Meeting.

CHICAGO — Efforts to modify treatments in an attempt to preserve high cure rates while reducing potential late effects have translated to improved health outcomes for childhood cancer survivors, Todd M. Gibson, PhD, assistant member at St. Jude Children’s Research Hospital, said at the ASCO Annual Meeting.

CHICAGO — ASCO’s big-data initiative CancerLinQ announced a long-term partnership with the FDA to use patient data to evaluate the real-world use of newly approved cancer therapies, according to a press release.

Carl H. June, MD, received this year’s David A. Karnofsky Memorial Award.

CHICAGO — Treatment modifications that extended survival for childhood cancer survivors during the past several decades also reduced incidence of serious chronic disease in these individuals later in life, according to study results presented at the ASCO Annual Meeting.

National Cancer Survivors Day, recognized annually on the first Sunday in June, provides free education and networking to hospitals, support groups and other cancer-related organizations to help improve the quality of life of cancer survivors.

Michael A. Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center, took over this spring as president of American Association for Cancer Research.

A treatment regimen that included the inexpensive anti-malaria drug chloroquine dramatically improved survival and quality of life for three patients with glioblastoma, according to researchers from University of Colorado Cancer Center.